Clinical Trial Update: Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting a multiple-dose study of ATN-103 in subjects with active rheumatoid arthritis, conducted in Phase 1/2, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ATN-103

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Active Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED